<DOC>
	<DOC>NCT00308685</DOC>
	<brief_summary>This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma. The dosing period lasts three weeks and starts following a three-week run-in period.</brief_summary>
	<brief_title>Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Albuterol</mesh_term>
	<criteria>Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening Male and female children aged 411 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 6090% Ability to perform spirometry Demonstrate 12% airways reversibility Require continuous treatment with betablockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids Presence of any nonasthmatic clinicallysignificant acute or uncontrolled chronic diseases</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pediatric asthma</keyword>
</DOC>